Immunotherapy Combination Explored in Unresectable HCC – OncLive
OncLive |
Immunotherapy Combination Explored in Unresectable HCC
OncLive Investigators are looking into a combination of immunotherapy agents for patients with unresectable hepatocellular carcinoma (HCC), for whom there are limited treatment options in the first line. Researchers think the combination of durvalumab (Imfinzi … |
